following a full submission assessed under the end of life and ultra-orphan medicine processes:
lenvatinib (Lenvima®) is accepted for use within NHS Scotland.
Indication under review: treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
Lenvatinib, compared with placebo, significantly improved progression free survival in adults with RAI-refractory DTC.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of lenvatinib. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.
Download detailed advice281KB (PDF)
Medicine details
- Medicine name:
- lenvatinib (Lenvima)
- SMC ID:
- 1179/16
- Indication:
- treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
- Pharmaceutical company
- Eisai Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 October 2016